What happened
UK researchers at the University of Cambridge conducted the first human trial of an AI-designed "universal vaccine" intended to protect against sarbecoviruses like SARS, MERS, and COVID-19. The Phase 1 trial, involving nearly 40 participants from late 2021 to 2023, reported no serious side effects. However, the vaccine showed only a "modest" impact on immune systems, with data not supporting a "robust vaccine-induced increase in antibody responses beyond pre-existing levels," per the study published in the Journal of Infection.
Why it matters
Initial human trial results for an AI-designed universal vaccine indicate a limited immune response, challenging the immediate impact of AI in broad-spectrum vaccine development. While the AI-designed antigen aimed to future-proof against multiple pathogens, the "modest" immune system impact and lack of robust antibody increase in Phase 1 suggest a longer development path. Public health officials and investors in AI-driven drug discovery should monitor subsequent Phase 2 trials for evidence of improved efficacy, as current data indicates this approach requires significant further validation.
